05/12/22 8:00 AMNasdaq : ATRS, HALO acquisitionHart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares PharmaHalozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the " HSR Act"), applicable to Halozyme's proposed acquisition of Antares Pharma,RHEA-AIneutral
04/13/22 5:41 PMNasdaq : ATRS, OBNK, SRRA SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates SRRA, ATRS, OBNKHalper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:Sierra Oncology , Inc. (NASDAQ: SRRA)'s sale toRHEA-AIneutral
04/13/22 8:08 AMNasdaq : ATRS ATRS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Antares Pharma, Inc. Is Fair to ShareholdersHalper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Antares Pharma, Inc. to Halozyme Therapeutics, Inc. for $5.60 per share in cash is fair to Antares Pharma shareholders. Halper Sadeh encourages Antares Pharma shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper...RHEA-AIneutral
04/13/22 6:00 AMNasdaq : HALO, ATRS acquisitionHalozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery LeaderTransaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and BeyondAugments Drug Delivery Business with Best-in-Class Auto Injector Platform with Broad Licensing PotentialDiversifies Revenue MixRHEA-AIvery positive
03/29/22 7:00 AMNasdaq : ATRS fda approvalAntares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement TherapyAntares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration granted final approval for TLANDO™ (testosterone undecanoate),RHEA-AIvery positive
03/03/22 7:00 AMNasdaq : ATRS Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating ResultsFull-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2 Million 2022 Revenue Guidance Range of $200 to $220 Million EWING, N.J., March 03, 2022 (GLOBERHEA-AIpositive
02/28/22 8:30 AMNasdaq : ATRS conferencesAntares Pharma to Present at the Cowen 42nd Annual Healthcare ConferenceAntares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Cowen 42 ndRHEA-AIneutral
02/17/22 8:30 AMNasdaq : ATRS conferencesAntares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating ResultsAntares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens.RHEA-AIneutral
02/03/22 8:00 AMNasdaq : ATRS Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted its New Drug Application (“NDA”)RHEA-AIvery positive
01/18/22 7:30 AMNasdaq : ATRS Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis RescueAntares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for ATRS-1902 for adrenal crisis rescue. The developmentRHEA-AIvery positive